Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;27(2):151-6.
doi: 10.1097/CCO.0000000000000158.

Intralesional therapy for advanced melanoma: promise and limitation

Sanjiv S Agarwala  1
Affiliations
Free PMC article
Review

Intralesional therapy for advanced melanoma: promise and limitation

Sanjiv S Agarwala. Curr Opin Oncol. 2015 Mar.
Free PMC article

Abstract

Purpose of review: Patients with unresectable, multiple or advanced locally/regionally metastatic stage IIIB/C or stage IV M1a melanoma have a high risk for recurrence, progression and metastasis. The article reviews treatment advances for this population.

Recent findings: After promising phase 2 results with Allovectin-7 (velimogene aliplasmid), overall survival in a phase 3 study was shorter for Allovectin-7 than for dacarbazine/temozolomide (median 18.8 versus 24.1 months).In a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 among 28 patients with advanced melanoma, the primary endpoint of best overall response rate within 24 weeks of first treatment was 32.2% for objective response and 10.7% for complete response.In the phase 3 OPTiM trial of talimogene laherparepvec, the intralesional agent that is furthest along in clinical testing, the primary endpoint of durable response rate was 16% for talimogene laherparepvec and 2% for granulocyte macrophage colony-stimulating factor.In the PV-10 phase 2 trial among 80 patients with stage III-IV melanoma, the overall response rate was 51%, with a 26% complete response rate.

Summary: Despite advances, many patients will need several lines of therapy. Some will not be eligible for systemic therapy. Their low toxicity, easy administration and likely systemic immune effects make intralesional therapies an attractive option.

PubMed Disclaimer

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. John HE, Mahafffey PJ. Ablation and cryotherapy of melanoma metastases. J Surg Oncol 2014; 109:296–300. - PubMed

    2. Comprehensive and recent review of ablative therapy and cryotherapy for cutaneous melanoma metastases.

    1. Campana LG, Testori A, Mozzillo N, Rossi CR. Treatment of metastatic melanoma with electrochemotherapy. J Surg Oncol 2014; 109:301–307. - PubMed

    2. Recent review on technique of electrochemotherapy, a modality more widely used in Europe than North America.

    1. Temple-Oberle CF, Byers BA, Hurdle V, et al. Intra-lesional interleukin-2 therapy for in transit melanoma. J Surg Oncol 2014; 109:327–331. - PubMed

    2. Intralesional IL-2 has been a treatment that has been available for many years. This is the most recent and complete review of the subject.

    1. Thompson JF. Local and regional therapies for melanoma: many arrows in the quiver. J Surg Oncol 2014; 109:29. - PubMed
    1. Mastrangelo MJ, Bellet RE, Berkelhammer J, Clark WH., Jr Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer 1975; 36:1305–1308. - PubMed

MeSH terms